A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia

Phase 2

Completed

• Conditions: Severe Hypertriglyceridemia; Mixed Dyslipidaemia
• Interventions: Drug: Placebo; Drug: Gemcabene

• Registration Number: NCT02944383
• Lead Sponsor: NeuroBo Pharmaceuticals Inc.

Brief Summary

A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-10-24
• Study First Submitted QC: 2016-10-24
• Study First Posted: 2016-10-25
• Study Start: 2016-12
• Primary Completion: 2018-01-11
• Study Completion: 2018-05-09
• Status Verified: 2020-06
• Results First Submitted: 2020-06-03
• Results First Submitted QC: 2020-06-03
• Last Update Submitted: 2020-06-03
• Results First Posted: 2020-06-25
• Last Update Posted: 2020-06-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 91

Inclusion Criteria

Subjects who meet all of the following criteria will be eligible to participate in the study:

1. Provision of written and signed informed consent (by subject or legal guardian) prior to any study-specific procedure;

2. Male or female (neither pregnant or lactating) ≥18 years of age at time of consent;

   1. Women of child-bearing potential must have a negative serum pregnancy test at the Screening Visit and negative urine dipstick on Study Day 1 prior to dosing in order to qualify for the study. Women who are surgically sterile or are clinically confirmed to be post-menopausal (i.e., documented amenorrhea for ≥ 1 year in the absence of other biological or physiological causes) are not considered to be of child-bearing potential;
   2. Women of child-bearing potential must agree to use acceptable methods of contraception throughout the duration of the study and for 30 days after the last dose of study drug. For this study, double-barrier contraception is required.

3. Currently on a self-reported, stable, low-fat, low-cholesterol diet in combination with stable statins with or without ezetimibe (10 mg QD) for at least 12 weeks prior to the Screening Visit;

4. Mean fasting TG value ≥ 500 mg/dL to < 1500 mg/dL (with the higher value no more than 50% greater than the lower value) from the S1 and S2 Visits (or alternatively S2 and S3);

5. Physical examination, including vital signs, that is within normal limits or clinically acceptable to the Investigator;

6. Weight ≥ 50 kg; with a body mass index (BMI) ≤ 45 kg/m²; and

7. Subjects with Type 2 diabetes who take anti-diabetes pharmacologic therapy must be on a stable a regimen for at least 3 months, with no planned changes in medications for the study duration.

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from participation in the study:

1. Known and previously documented homozygous genetic deficiencies (LPL, ApoC-II, ApoC-III, ApoA-V, GPIHBP1, or LMF1);
2. History of pancreatitis within the last 6 months prior to screening (Visit S1);
3. History of bariatric surgery; symptomatic gallstone disease, unless treated with cholecystectomy;
4. Abnormal liver function test at the Pre-Screening Visit or any of the Screening Visits (aspartate aminotransferase or alanine aminotransferase > 2 × the upper limit of normal [ULN], total bilirubin > 1.5 × ULN, or alkaline phosphatase > 2 × ULN based on appropriate age and gender normal values). Subjects with bilirubin > 1.5 × ULN and history of Gilbert's syndrome may be included; reflexive direct bilirubin testing will be used to confirm Gilbert's syndrome;
5. Active liver disease (e.g., cirrhosis, alcoholic liver disease, hepatitis B [HBV], hepatitis C [HCV], autoimmune hepatitis, liver failure, liver cancer), history of liver transplant, known diagnosis of human immunodeficiency virus (HIV), or acquired immune deficiency virus;
6. Moderate to severe renal insufficiency defined as an estimated GFR < 60 mL/min/1.73 m2 (calculated using The Chronic Kidney Disease Epidemiology Collaboration equation) at the Pre-Screening Visit or at any of the Screening Visits;
7. Abnormal urinalysis (proteinuria greater than trace or any male or non-menstruating female with greater than trace hematuria), confirmed by reflexive urine protein:creatinine ratio testing;
8. Uncontrolled thyroid disease: hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) below the lower limit of normal or > 1.5 × ULN, respectively, based on results from the Pre-Screening Visit or the Screening Visit. If controlled, treatment should be stable for at least 3 months prior to the Screening Visit;
9. Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus HbA1c value ≥8.5% based on results from the Pre-Screening Visit or the Screening Visit), or any diabetic subject taking a thiazolidinedione (e.g., pioglitazone, rosiglitazone);
10. New York Heart Association Class III or IV heart failure (see Appendix C);
11. Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, or other major cardiovascular events resulting in hospitalization within 3 months of the Screening Visit (S1). Subjects with adequately treated stable angina, per Investigator assessment, may be included;
12. Uncontrolled cardiac arrhythmia or prolonged QT on the Screening Visit or Study Day 1 prior to dosing ECG (QTcF > 450 msec for men and >470 msec for women) or known family history of prolonged QT or unexplained sudden cardiac death;
13. Uncontrolled hypertension, defined as sitting systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg, and confirmed by repeat measurement;
14. Currently receiving cancer treatment(s) or, in the Investigator's opinion, at risk of relapse for recent cancer;
15. Inadequate washout of a PCSK9 inhibitor (8 weeks prior to the Screening Visit S1), a fibrate lipid lowering agent (6 weeks prior to the Screening Visit S1), niacin > 200 mg/day, OMG-3, bile acid sequestrants or other lipid lowering therapies (4 weeks prior to the Screening Visit S1);
16. Use of any excluded medications or supplements within 3 months prior to S1 (e.g., potent cytochrome P450 [CYP] 3A4 inhibitors, see Appendix D);
17. Hypersensitivity to or a history of significant adverse reactions to any fibrate lipid regulating agent;
18. History of drug or alcohol abuse within the past year or inability to comply with protocol requirements, including subject alcohol restrictions (see Section 5.6.3);
19. Previously treated with gemcabene (i.e., CI-1027); participation in another clinical study of an investigational agent or device concurrently or within 1 month prior to the Screening Visit, or use of an investigational agent within 1 month or 5 half-lives (if known), whichever is longer, prior to the Screening Visit; or
20. Any other finding which, in the opinion of the Investigator, would compromise the subject's safety or participation in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Participants received matching placebo orally, once daily for 12 weeks.
Gemcabene 300 mg	Gemcabene	Participants received 300 mg Gemcabene orally, once daily for 12 weeks.
Gemcabene 600 mg	Gemcabene	Participants received 600 mg Gemcabene orally, once daily for 12 weeks.

Primary Outcome Measures

Name	Time	Method
Percent Change From Baseline to End of Study (EOS) in Fasting Serum Triglycerides (TG)	Baseline, EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using last observation carried forward (LOCF).

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Angiopoietin 4	Baseline, Week 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in Interleukin-6	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in Interleukin-6	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in HDL Particle Number	Baseline, Week 12
Percent Change From Baseline in Apolipoprotein B	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in LDL-TG	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in VLDL-TG	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in Fibrinogen	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in Apolipoprotein B	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in TC	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in TC	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in Non-HDL-C	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in Apolipoprotein A-I	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in Apolipoprotein A-II	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in Apolipoprotein A-II	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in Non-HDL-C	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in Apolipoprotein A-I	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in Apolipoprotein C-II	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in Apolipoprotein C-II	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in Apolipoprotein E	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in LDL-C	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in HDL-C	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in LDL-TG	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in HDL-TG	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in High-sensitivity C-reactive Protein	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in Angiopoietin 4	Baseline, Week 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in High-sensitivity C-reactive Protein	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in Serum Amyloid A	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in Apolipoprotein C-III	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in Lipoprotein Size	Baseline, Week 12	Percent change from baseline in Particle size for VLDL, HDL and LDL were reported.
Change From Baseline in Lipoprotein Size	Baseline, Week 12	Change from baseline in Particle size for VLDL, HDL and LDL were reported.
Change From Baseline in Lipoprotein Particle Number	Baseline, Week 12	Change from baseline in particle number for VLDL \& chylomicron, LDL and IDL were reported.
Percent Change From Baseline in Adiponectin	Baseline, Week 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in Fasting Serum TG	Baseline, Weeks 2, 6, 10 and 12
Percent Change From Baseline in VLDL-C	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in VLDL-C	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in HDL-C	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in Fasting Serum TG	Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in Lipoprotein Particle Number	Baseline, Week 12	Percent change from baseline in particle number for VLDL \& chylomicron, LDL and IDL were reported.
Percent Change From Baseline in HDL Particle Number	Baseline, Week 12
Change From Baseline in Apolipoprotein C-III	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in Apolipoprotein E	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in LDL-C	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in VLDL-TG	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in HDL-TG	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in Fibrinogen	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percent Change From Baseline in Serum Amyloid A	Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Change From Baseline in Adiponectin	Baseline, Week 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.
Percentage of Participants Achieving a TG Value < 500 mg/dL (5.65 mmol/L)	Weeks 10, 12 and EOS (average of week 10 and 12)	EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using LOCF.

Trial Locations

Locations (46)

Soma Medical Research; 🇺🇸 West Palm Beach, Florida, United States

University of Maryland Medical Center; 🇺🇸 Baltimore, Maryland, United States

Physicians East, NA; 🇺🇸 Greenville, North Carolina, United States

Optimed Research; 🇺🇸 Columbus, Ohio, United States

Sante Clinical Research; 🇺🇸 Kerrville, Texas, United States

Clinical Investigation Specialists; 🇺🇸 Kenosha, Wisconsin, United States

SC Clinical Research; 🇺🇸 Garden Grove, California, United States

San Marcus Research Clinic, Inc.; 🇺🇸 Miami, Florida, United States

Millenium Clinical Research, Inc.; 🇺🇸 Miami, Florida, United States

Medcare Research; 🇺🇸 Miami, Florida, United States

Midwest Institute for Clinical Research, Inc.; 🇺🇸 Indianapolis, Indiana, United States

Airline Complete Healthcare; 🇺🇸 Houston, Texas, United States

National Research Institute; 🇺🇸 Los Angeles, California, United States

Paradigm Research; 🇺🇸 Wheat Ridge, Colorado, United States

Clinical Research of South Nevada; 🇺🇸 Las Vegas, Nevada, United States

Indago Research and Health Center; 🇺🇸 Hialeah, Florida, United States

Direct Helpers Research Center; 🇺🇸 Hialeah, Florida, United States

AR Developoment Solutions; 🇺🇸 Miami Lakes, Florida, United States

Sunrise Medical Research; 🇺🇸 Lauderdale Lakes, Florida, United States

Del Sol Research Mangagement, LLC; 🇺🇸 Tucson, Arizona, United States

Elite Clinical Research; 🇺🇸 Jackson, Mississippi, United States

Carolinas Research Partners, LLC; 🇺🇸 Rock Hill, South Carolina, United States

Clinical Trials Management, LLC; 🇺🇸 Metairie, Louisiana, United States

Meridien Research; 🇺🇸 Bradenton, Florida, United States

Ecogene-21; 🇨🇦 Chicoutimi, Quebec, Canada

Excel Medical Research; 🇺🇸 Boca Raton, Florida, United States

Appalachian Research Associates; 🇺🇸 Fort Payne, Alabama, United States

Westside Medical Associates of Los Angeles; 🇺🇸 Beverly Hills, California, United States

Hope Clinical Research; 🇺🇸 Canoga Park, California, United States

Paradigm Clinical Research; 🇺🇸 San Diego, California, United States

Jacksonville Center for Clinical Research; 🇺🇸 Jacksonville, Florida, United States

Evanston Premier Clinical Research; 🇺🇸 Evanston, Illinois, United States

Richard Lochamy, M.D.; 🇺🇸 Junction City, Kansas, United States

Eastern Carolina Medical Clinic; 🇺🇸 Benson, North Carolina, United States

FMC Science; 🇺🇸 Lampasas, Texas, United States

Cary Medical Clinic; 🇺🇸 Morrisville, North Carolina, United States

PriMed Clinical Research; 🇺🇸 Dayton, Ohio, United States

Green and Seidner Family Practice Associates; 🇺🇸 Lansdale, Pennsylvania, United States

BTC of Lincoln; 🇺🇸 Lincoln, Rhode Island, United States

Sun Research Institute; 🇺🇸 San Antonio, Texas, United States

Clinical Investigations of Texas; 🇺🇸 Plano, Texas, United States

L-MARC Research Center; 🇺🇸 Louisville, Kentucky, United States

University of Michigan Health Systems; 🇺🇸 Ann Arbor, Michigan, United States

CHEAR Center, LLC; 🇺🇸 Bronx, New York, United States

Advantage Clinical Trials; 🇺🇸 Bronx, New York, United States

University of Kansas Medical Center; 🇺🇸 Kansas City, Kansas, United States